. 2019 Nov 26;5(11):e02904. doi: 10.1016/j.heliyon.2019.e02904

Table 4.

Meta-analysis results for other efficacy related outcome measures (FAS).

Outcome measure	N		Mean value difference and 95% CI
Outcome measure	EPs 7630	Placebo	Mean value difference and 95% CI
Days off work^a	412	409	-0·74 [-1·33; -0·15]
Paracetamol consumption (mg)^a,^c	416	416	-79·0 [-152·4; -5·5]
Days until the onset of a treatment effect^a	393	395	-1·12 [-2·14; -0·10]
IMOS – investigator rating, day 5^a	416	416	-0·39 [-0·72; -0·06]
Sleep quality – sum of item scores, day 5^b	405	401	1·63 [0·45; 2·81]

Point estimates <0 favor EPs 7630.

Point estimates >0 favor EPs 7630.

Patients who did not use paracetamol were included in the calculation with a value of 0.